Form 4: Actuate Therapeutics Director Receives Stock Option Grant

Director Martin H. Huber Jr. was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Martin H. Huber Jr. acquired 15,000 stock options in Actuate Therapeutics, Inc. (ACTU).
• The options have an exercise price of $2.42 per share.
• The grant date for these options is May 21, 2026.
• The options are set to expire on May 21, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's immediate financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.42 exercise price.

Future Outlook

The options vest in full on the first anniversary of the grant date, May 21, 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the biotechnology sector.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The 10-year expiration term is standard for executive and director equity incentive plans.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of the 15,000 options on May 21, 2027.

Key Dates

Keywords

Actuate Therapeutics, ACTU, Form 4, Insider Trading, Stock Options, Director Compensation